Compare Koninklijke Philips NV (PHG) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs 10X Genomics Inc — how do they compare? Koninklijke Philips NV trades at $24.31 (market cap $23.52B), while 10X Genomics Inc trades at $83.55 (market cap $10.07B). The key difference: Koninklijke Philips NV is far larger — about 2.3× 10X Genomics Inc's market cap, and Koninklijke Philips NV pays a 4.17% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Koninklijke Philips NV for 84 Days and 10X Genomics Inc for 92 Days on average.
| PHG | TXG | |
|---|---|---|
Market Cap | $23.52B | $10.07B |
Volume | 1,635,069 | 5,657,286 |
Sector | Health | Health |
52-Week High | $32.91 | $97.74 |
52-Week Low | $23.81 | $11.48 |
Typical Hold Time | 84 Days | 92 Days |
Enterprise Value | $29.87B | $9.59B |
Dividend Yield | 4.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $24.09, down 0.25% with a bearish technical signal. The company shows improving fundamentals with three consecutive quarterly EPS beats and a return to profitability in 2025 (net income $895M). Recent news highlights innovation in healthcare technology including new product launches and AI partnerships. Valuation metrics appear reasonable with P/E of 18.94 and P/S of 1.18.
PHG presents a mixed outlook with strong operational recovery but technical weakness. The investment case hinges on continued earnings momentum and successful execution of healthcare technology initiatives. Key risks include competitive pressures and potential cybersecurity vulnerabilities following recent hacking incidents. Analyst consensus leans neutral with 36% buy ratings versus 64% hold.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
